Elanco Animal Health Inc (ELAN) reports robust organic growth and significant debt reduction, setting a positive outlook for ...

Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...

Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...

Highlights,Elanco Animal Health reported a miss in earnings, with EPS falling short of expectations.,Analysts adjusted their ...

Elanco Animal Health (NYSE:ELAN) stock falls as the company reports mixed Q4 2024 results, and sets 2025 outlook below consensus due to forex headwinds. Read more here.

Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.

Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.

Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...

Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.